Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
First Claim
Patent Images
1. A peptide consisting of a region of troponin subunit I having amino acid residues 130-137 (huTnI130-137) of SEQ ID NO:
- 17.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments, or homologs thereof, for the treatment of diseases or disorders involving abnormal angiogenesis and methods of use thereof.
38 Citations
42 Claims
-
1. A peptide consisting of a region of troponin subunit I having amino acid residues 130-137 (huTnI130-137) of SEQ ID NO:
- 17.
-
2. A peptide consisting of a region of troponin subunit I having amino acid residues 132-139 (huTnI132-139) of SEQ ID NO:
- 17.
-
3. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide in which the peptide has greater than 80% identity with amino acid residues consisting of 130-137 (huTnI130-137) of SEQ ID NO:
- 17 and a pharmaceutically acceptable carrier.
- View Dependent Claims (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
4. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide in which the peptide has greater than 80% identity with amino acid residues consisting of 132-139 (huTnI132-139) of SEQ ID NO:
- 17 and a pharmaceutically acceptable carrier.
-
5. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide with amino acid residues consisting of 130-137 (huTnI130-137) of SEQ ID NO:
- 17 and a pharmaceutically acceptable carrier.
-
6. A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder comprising a peptide with amino acid residues consisting of 132-139 (huTnI132-139) of SEQ ID NO:
- 17 and a pharmaceutically acceptable carrier.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeBoston Life Sciences Incorporated, Children's Medical Center Corporation
-
Original AssigneeBoston Life Sciences Incorporated, Children's Medical Center Corporation
-
InventorsMoses, Marsha A., Lanser, Marc E., Wiederschain, Dmitri G., Thorn, Richard M.
-
Primary Examiner(s)BORIN, MICHAEL L
-
Application NumberUS09/442,099Time in Patent Office1,063 DaysField of Search514/16, 530/328US Class Current424/1.11CPC Class CodesA61K 38/1709 from mammalsC07K 14/4716 Muscle proteins, e.g. myosi...
